Tysabri Withdrawal Prompts Biogen Idec To Suspend Financial Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to issue revised guidance in May after warning investors not to rely on previous financial forecasts. Announcement coincides with news that a third diagnosis of PML was discovered in a clinical trial for Tysabri.